Stocks › AXSM

Axsome Therapeutics, Inc.

AXSM·Nasdaq·United States United States·USD
$129.36
-6.32 (-4.66%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
AXSM
Axsome Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
AXSMS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of AXSM by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Christopher L. JacobsChristopher L. JacobsHouse · R · NY AXSMAxsome Therapeutics, Inc. · Stock Purchase
$15,001 - $50,000
Jul 28, 2022 Jun 16, 2022 Filing ↗

Whale Activity

Position changes in AXSM reported for 2026-09-30 by 563 institutional filers
Increased: 177New: 60Held: 62Decreased: 149Closed: 97No prior filing: 18
  • Increased177
  • New60
  • Held62
  • Decreased149
  • Closed97
  • No prior filing18
FilerSharesValueChange
BlackRock, Inc.3.5M$636.5Mincreased
VANGUARD CAPITAL MANAGEMENT LLC2.0M$370.1Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC2.0M$363.7Mdecreased
Invesco Ltd.1.9M$355.9Mincreased
FMR LLC1.4M$266.3Mdecreased
MILLENNIUM MANAGEMENT LLC1.3M$244.0Mincreased
TWO SIGMA INVESTMENTS, LP1.1M$204.8Mincreased
GEODE CAPITAL MANAGEMENT, LLC1.0M$186.3Mincreased
UBS Group AG849.8K$156.7Mincreased
STATE STREET CORP823.3K$151.8Mincreased
Deep Track Capital, LP800.0K$147.5Mincreased
BANK OF AMERICA CORP /DE/740.7K$136.6Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by AXSM insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: -15.0K2025 Q12025 Q2: -112.2K2025 Q22025 Q3: -236.4K2025 Q32025 Q4: -326.9K2025 Q42026 Q1: -251.7K2026 Q12026 Q2: -114.3K2026 Q22026 Q3: -109.3K2026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

184 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Jacobson Mark L.Chief Operating Officer Sale −10.0K $208.65 $2.1M Sep 3, 2026 Form 4 ↗
Jacobson Mark L.Chief Operating Officer Option exercise +10.0K $12.95 $130K Sep 3, 2026 Form 4 ↗
TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner Sale −4,660 $213.95 $997K Aug 6, 2026 Form 4 ↗
TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner Option exercise +4,660 $4.95 $23K Aug 6, 2026 Form 4 ↗
TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner Sale −45.0K $212.01 $9.5M Aug 5, 2026 Form 4 ↗
TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner Option exercise +45.0K $4.95 $223K Aug 5, 2026 Form 4 ↗
TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner Sale −49.7K $240.25 $11.9M Jul 1, 2026 Form 4 ↗
TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner Option exercise +49.7K $4.95 $246K Jul 1, 2026 Form 4 ↗
JEFFS ROGERDirector Sale −286 $249.12 $71K Jun 11, 2026 Form 4 ↗
JEFFS ROGERDirector Sale −286 $246.18 $70K Jun 10, 2026 Form 4 ↗
Mahony SusanDirector Sale −300 $246.18 $74K Jun 10, 2026 Form 4 ↗
Coleman MarkDirector Sale −643 $249.00 $160K Jun 10, 2026 Form 4 ↗
Mahony SusanDirector Sale −300 $237.21 $71K Jun 9, 2026 Form 4 ↗
TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner Sale −49.7K $241.01 $12.0M Jun 9, 2026 Form 4 ↗
TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner Option exercise +49.7K $4.95 $246K Jun 9, 2026 Form 4 ↗
Pizzie NickChief Financial Officer Sale −33.0K $240.09 $7.9M Jun 9, 2026 Form 4 ↗
Pizzie NickChief Financial Officer Option exercise +33.0K $3.50 $116K Jun 9, 2026 Form 4 ↗
JEFFS ROGERDirector Option exercise +1,429 — — Jun 8, 2026 Form 4 ↗
Saad Mark EDirector Option exercise +1,429 — — Jun 8, 2026 Form 4 ↗
Mahony SusanDirector Option exercise +1,429 — — Jun 8, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding AXSM · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.4M$339.9M0.01%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
1.0M$245.6M0.13%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
578.2K$141.5M0.30%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
495.8K$121.3M0.12%Jun 30, 2026
VANGUARD EXPLORER FUND531.0K$115.8M0.52%Jul 31, 2026
Invesco Discovery Fund
AIM Counselor Series Trust (Invesco Counselor Series Trust)
535.3K$106.3M1.43%Aug 31, 2026
First Trust NYSE Arca Biotechnology Index Fund
First Trust Exchange-Traded Fund
426.1K$104.3M3.71%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
409.7K$85.1M0.26%Apr 30, 2026
iShares Biotechnology ETF
iShares Trust
305.1K$74.7M0.82%Jun 30, 2026
Franklin Dynatech Fund
Franklin Custodian Funds
300.0K$73.4M0.24%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list AXSM's shares (CUSIP 05464T104), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 2.7M shares5.3%
    Jul 27, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Axsome Therapeutics, Inc. as client

No lobbying filings found naming Axsome Therapeutics, Inc. as the client.

Government Contracts

Federal awards to Axsome Therapeutics, Inc. · USAspending

No federal contract awards found for Axsome Therapeutics, Inc..

U.S. Patents

Recent USPTO applications naming Axsome Therapeutics, Inc.

No USPTO patent applications found for Axsome Therapeutics, Inc..

Annual Financials

From AXSM's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$638.5M$385.7M$270.6M$0n/a
Operating income-$166.8M-$280.6M-$231.8M-$179.8M-$124.7M
Net income-$183.2M-$287.2M-$239.2M-$187.1M-$130.4M
Diluted EPS-$3.68-$5.99-$5.27-$4.60-$3.47
Operating cash flow-$93.4M-$128.4M-$145.1M-$116.5M-$108.2M
Cash and equivalents$322.9M$315.4M$386.2M$200.8M$86.5M
Total assets$689.8M$568.5M$588.2M$331.5M$87.8M
Total liabilities$601.5M$511.5M$397.3M$221.9M$72.2M
Shareholders' equity$88.3M$57.0M$191.0M$109.6M$15.6M

As Axsome Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 23, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in AXSM's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsNov 2, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsAug 10, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJul 15, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 9.01Officer / director changeJun 9, 2026
    EDGAR ↗
  • 8-K · Items 5.07, 9.01Shareholder voteJun 9, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJun 3, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsMay 4, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsDec 31, 2025
    EDGAR ↗

About Axsome Therapeutics, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNEW YORK, NY
IncorporatedDE